Evidence map›Paper›PMID 26202232›Full record

ArticleJournal of virology2015

Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1.

Justin Pollara, Erin McGuire, Genevieve G Fouda, Wes Rountree, Josh Eudailey, R Glenn Overman, Kelly E Seaton, Aaron Deal, R Whitney Edwards, Gerald Tegha and 15 more

Open access · bronzeAbstract readControlled Clinical Trial
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 62 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Gut microbiome and breast-feeding: Implications for early immune development.The Journal of allergy and clinical immunology · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. COVID-19 and human milk: SARS-CoV-2, antibodies, and neutralizing capacity.medRxiv : the preprint server for health sciences · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 1 country.

Justin PollaraDepartment of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
Erin McGuireHuman Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Genevieve G FoudaHuman Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Wes RountreeHuman Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Josh EudaileyHuman Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
R Glenn OvermanHuman Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Kelly E SeatonHuman Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Aaron DealHuman Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
R Whitney EdwardsDepartment of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
Gerald TeghaThe University of North Carolina Project, Lilongwe, Malawi.
Deborah KamwendoThe University of North Carolina Project, Lilongwe, Malawi.
Jacob KumwendaThe University of North Carolina Project, Lilongwe, Malawi.
Julie A E NelsonDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Hua-Xin LiaoHuman Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Christie BrinkleyHuman Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Thomas N DennyHuman Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Christina OchsenbauerDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Sascha EllingtonDivision of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Caroline C KingDivision of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Denise J JamiesonDivision of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Charles van der HorstDivision of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Athena P KourtisDivision of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Georgia D TomarasHuman Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Guido FerrariDepartment of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
Sallie R PermarHuman Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA sallie.permar@dm.duke.edu.
Duke University · USCenters for Disease Control and Prevention · USUniversity of North Carolina at Chapel Hill · USNational Center for Chronic Disease Prevention and Health Promotion · USUniversity of Alabama at Birmingham · US

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2006 to 2011
$290.5M
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Ellen Florence Eaton · 1988 to 2026
$84.1M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5M
UNC CENTER FOR HEALTH PROMOTION AND DISEASE PREVENTIONU48DP001944 · DP · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AMMERMAN, ALICE S · 2009 to 2013
$15.1M
UNC Center for Health Promotion and Disease PreventionU48DP000059 · DP · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AMMERMAN, ALICE S · 2004 to 2009
$14.4M
AIDS INTERNATIONAL TRAINING AND RESEARCH PROGRAMD43TW001039 · FIC · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ADIMORA, ADAORA A · 1998 to 2013
$9.9M
Transmission-blocking potential of novel HIV Env-specific mucosal antibodiesR01AI106380 · NIAID · DUKE UNIVERSITY · PI PERMAR, SALLIE R. · 2013 to 2017
$3.4M
ACL HHS U48DP001944FIC NIH HHS DHHS/NIH/FIC 2-D43 TW01039-06FIC NIH HHS R24 TW00798NCCDPHP CDC HHS SIP 22-09 U48-DP001944-01NCCDPHP CDC HHS SIP 26-04 U48-DP000059-01NCCDPHP CDC HHS U48 DP000059NCCDPHP CDC HHS U48 DP001944NIAID NIH HHS 5P30 AI050410NIAID NIH HHS 5P30AI064518NIAID NIH HHS AI06380NIAID NIH HHS AI100645NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI064518NIAID NIH HHS P30-AI50410NIAID NIH HHS R01 AI106380NIAID NIH HHS U19 AI067854NIAID NIH HHS UM1 AI100645PHS HHS SIP 13-01U48-CCU409660-09
6 · The paper itself

Abstract

unlabelledInfants born to HIV-1-infected mothers in resource-limited areas where replacement feeding is unsafe and impractical are repeatedly exposed to HIV-1 throughout breastfeeding. Despite this, the majority of infants do not contract HIV-1 postnatally, even in the absence of maternal antiretroviral therapy. This suggests that immune factors in breast milk of HIV-1-infected mothers help to limit vertical transmission. We compared the HIV-1 envelope-specific breast milk and plasma antibody responses of clade C HIV-1-infected postnatally transmitting and nontransmitting mothers in the control arm of the Malawi-based Breastfeeding Antiretrovirals and Nutrition Study using multivariable logistic regression modeling. We found no association between milk or plasma neutralization activity, antibody-dependent cell-mediated cytotoxicity, or HIV-1 envelope-specific IgG responses and postnatal transmission risk. While the envelope-specific breast milk and plasma IgA responses also did not reach significance in predicting postnatal transmission risk in the primary model after correction for multiple comparisons, subsequent exploratory analysis using two distinct assay methodologies demonstrated that the magnitudes of breast milk total and secretory IgA responses against a consensus HIV-1 envelope gp140 (B.con env03) were associated with reduced postnatal transmission risk. These results suggest a protective role for mucosal HIV-1 envelope-specific IgA responses in the context of postnatal virus transmission. This finding supports further investigations into the mechanisms by which mucosal IgA reduces risk of HIV-1 transmission via breast milk and into immune interventions aimed at enhancing this response. IMPORTANCE: Infants born to HIV-1-infected mothers are repeatedly exposed to the virus in breast milk. Remarkably, the transmission rate is low, suggesting that immune factors in the breast milk of HIV-1-infected mothers help to limit transmission. We compared the antibody responses in plasma and breast milk of HIV-1-transmitting and -nontransmitting mothers to identify responses that correlated with reduced risk of postnatal HIV-1 transmission. We found that neither plasma nor breast milk IgG antibody responses were associated with risk of HIV-1 transmission. In contrast, the magnitudes of the breast milk IgA and secretory IgA responses against HIV-1 envelope proteins were associated with reduced risk of postnatal HIV-1 transmission. The results of this study support further investigations of the mechanisms by which mucosal IgA may reduce the risk of HIV-1 transmission via breastfeeding and the development of strategies to enhance milk envelope-specific IgA responses to reduce mother-to-child HIV transmission and promote an HIV-free generation.

Indexed as

HIV-1Infectious Disease Transmission, VerticalAdultAntibodies, NeutralizingAntibody-Dependent Cell CytotoxicityAntibody SpecificityBreast Feedingenv Gene Products, Human Immunodeficiency VirusFemaleHIV AntibodiesHIV InfectionsHumansImmunity, MucosalImmunoglobulin AImmunoglobulin A, SecretoryImmunoglobulin GAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency Virusgp140 envelope protein, Human immunodeficiency virus 1HIV AntibodiesImmunoglobulin AImmunoglobulin A, SecretoryImmunoglobulin G

Identifiers

PMID26202232
PMCPMC4577885
OpenAlexW1851275462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.